Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies

BACKGROUND: Patients with lymphoid malignancies are at risk for poor coronavirus disease 2019 (COVID-19)-related outcomes and have reduced vaccine-induced immune responses. Currently, a 3-dose primary regimen of mRNA vaccines is recommended in the United States for immunocompromised hosts. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Sherman, Amy C, Crombie, Jennifer L, Cheng, ChiAn, Desjardins, Michaël, Zhou, Guohai, Ometoruwa, Omolola, Rooks, Rebecca, Senussi, Yasmeen, McDonough, Mikaela, Guerrero, Liliana I, Kupelian, John, Doss-Gollin, Simon, Smolen, Kinga K, van Haren, Simon D, Armand, Philippe, Levy, Ofer, Walt, David R, Baden, Lindsey R, Issa, Nicolas C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384786/
https://www.ncbi.nlm.nih.gov/pubmed/36043177
http://dx.doi.org/10.1093/ofid/ofac417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384786/
https://www.ncbi.nlm.nih.gov/pubmed/36043177
http://dx.doi.org/10.1093/ofid/ofac417

Ejemplares similares